Payment overview · 2025
General Payments
$4,483.77
45 reported records · 19 companies
Healthcare provider profile · identity verified
Tarundeep Singh
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · ATLANTIS, FL · NPI 1013571694
Verified facts
What the public records show
CMS Open Payments records show Tarundeep Singh received $4,483.77 in general payments during 2025 across 45 reported records.
W. L. Gore & Associates, Inc. accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $1,775.78 | 39.6% | 7 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $945.66 | 21.1% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $237.62 | 5.3% | 3 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $230.16 | 5.1% | 2 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $211.24 | 4.7% | 3 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $205.83 | 4.6% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $124.99 | 2.8% | 1 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $120.23 | 2.7% | 1 | 2025 |
| Biocomposites Inc | Unresolved — no canonical attribution shown | $110.55 | 2.5% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $107.38 | 2.4% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $96.83 | 2.2% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $88.49 | 2.0% | 4 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $50.00 | 1.1% | 2 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $49.82 | 1.1% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $48.36 | 1.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.67 | 0.6% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $20.67 | 0.5% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $16.49 | 0.4% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $15.00 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,262.55 | 39 |
| Travel and Lodging | $1,425.66 | 4 |
| Long term medical supply or device loan | $795.56 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $1,617.44 | 6 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $945.66 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $230.16 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $230.16 | 2 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $211.24 | 3 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $205.83 | 3 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $158.34 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $153.05 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $150.10 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $150.10 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| ARISTA Normalized: arista |
Device | Davol Inc. | $120.23 | 1 | 2025 |
Source payment records
|
|||||
| Stimulan Normalized: stimulan |
Device | Biocomposites Inc | $110.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $107.38 | 4 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $107.38 | 4 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $67.45 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $56.55 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $55.54 | 3 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $49.82 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $48.36 | 2 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $40.28 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $32.95 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| PROLENE Normalized: prolene |
Device | Ethicon US, LLC | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,483.77 · 45 records | W. L. Gore & Associates, Inc. | AQUACEL AG+ EXTRA, ARISTA, ARTIX MT, AZUR CX DETACHABLE, COLLAGENASE SANTYL, CT THROMBECTOMY SYSTEM KIT, ENDURANT IIS, ENROUTE Transcarotid Stent, ETHICON, EVARREST, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, General - Vascular Intervention, Indigo System, Integra, Integra Dermal Regeneration Template, JOURNAVX, Kerecis GraftGuide, Kerecis SurgiClose, PRIMATRIX, PROLENE, Penumbra System, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, Restrata Wound Matrix, SURGICEL NU-KNIT, SURGIFLO Hemostatic Matrix, SYMPHONY CATHETER, Stimulan, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, VISTASEAL, Varithena Administration Pack | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error